Recent advances and future perspectives in the therapeutics of prostate cancer
GL Varaprasad, VK Gupta, K Prasad, E Kim… - … Hematology & Oncology, 2023 - Springer
Prostate cancer (PC) is one of the most common cancers in males and the fifth leading
reason of death. Age, ethnicity, family history, and genetic defects are major factors that …
reason of death. Age, ethnicity, family history, and genetic defects are major factors that …
Genitourinary cancer neoadjuvant therapies: current and future approaches
SS Nair, D Chakravarty, V Patel, N Bhardwaj… - Trends in Cancer, 2023 - cell.com
Neoadjuvant therapies can improve tolerability, reduce tumor volume to facilitate surgery,
and assess subsequent treatment response. Therefore, there is much enthusiasm for …
and assess subsequent treatment response. Therefore, there is much enthusiasm for …
ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer
G Devos, L Tosco, M Baldewijns, T Gevaert, K Goffin… - European Urology, 2023 - Elsevier
Background High-risk prostate cancer (PCa) patients have a high risk of biochemical
recurrence and metastatic progression following radical prostatectomy (RP). Objective To …
recurrence and metastatic progression following radical prostatectomy (RP). Objective To …
Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression
F Zhang, M Biswas, S Massah, J Lee… - Nucleic Acids …, 2023 - academic.oup.com
Numerous cancers, including prostate cancer (PCa), are addicted to transcription programs
driven by specific genomic regions known as super-enhancers (SEs). The robust …
driven by specific genomic regions known as super-enhancers (SEs). The robust …
An 18-gene signature of recurrence-associated endothelial cells predicts tumor progression and castration resistance in prostate cancer
BB Lin, Q Huang, B Yan, M Liu, Z Zhang, H Lei… - British Journal of …, 2024 - nature.com
Background The prognostic and therapeutic implications of endothelial cells (ECs)
heterogeneity in prostate cancer (PCa) are poorly understood. Methods We investigated …
heterogeneity in prostate cancer (PCa) are poorly understood. Methods We investigated …
[HTML][HTML] Targeting S6K/NFκB/SQSTM1/Polθ signaling to suppress radiation resistance in prostate cancer
A Clark, MR Villarreal, SB Huang, S Jayamohan… - Cancer Letters, 2024 - Elsevier
In this study we have identified POLθ-S6K-p62 as a novel druggable regulator of radiation
response in prostate cancer. Despite significant advances in delivery, radiotherapy …
response in prostate cancer. Despite significant advances in delivery, radiotherapy …
Neoadjuvant novel hormonal therapy followed by prostatectomy versus up-front prostatectomy for high-risk prostate cancer: a comparative analysis
Purpose: We sought to compare outcomes between neoadjuvant therapy with a novel
hormonal agent (NHA) prior to radical prostatectomy (neo-RP) and up-front radical …
hormonal agent (NHA) prior to radical prostatectomy (neo-RP) and up-front radical …
Changes in bone and mineral homeostasis after short-term androgen deprivation therapy with or without androgen receptor signalling inhibitor–substudy of a single …
Summary Background Prostate cancer (PCa) patients treated with androgen deprivation
therapy (ADT) have an increased fracture risk. Exploring biomarkers for early bone loss …
therapy (ADT) have an increased fracture risk. Exploring biomarkers for early bone loss …
MRI/transrectal ultrasound fusion-guided targeted biopsy and transrectal ultrasound-guided systematic biopsy for diagnosis of prostate cancer: a systematic review …
J Xie, C Jin, M Liu, K Sun, Z Jin, Z Ding… - Frontiers in …, 2022 - frontiersin.org
Purpose For men suspected of having prostate cancer (PCa), the transrectal ultrasound
(TRUS)-guided systematic biopsy (SB) was performed. MRI/TRUS fusion guided-targeted …
(TRUS)-guided systematic biopsy (SB) was performed. MRI/TRUS fusion guided-targeted …
The Association Between [68Ga] PSMA PET/CT Response and Biochemical Progression in Patients with High-Risk Prostate Cancer Receiving Neoadjuvant Therapy
M Chen, Y Fu, S Peng, S Zang, S Ai… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Our previous study found that the prostate-specific membrane antigen (PSMA) PET/CT
response of primary prostate cancer (PCa) to neoadjuvant therapy can predict the …
response of primary prostate cancer (PCa) to neoadjuvant therapy can predict the …